Skip to main content
Clinical Trials/NCT05796804
NCT05796804CompletedNot Applicable

Erector Spinae Block Versus PENG Block for Postoperative Analgesia After Total Hip Replacement

Papa Giovanni XXIII Hospital2 sites in 1 country64 target enrollmentStarted: April 13, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
64
Locations
2
Primary Endpoint
morphine consumption

Study Overview

Brief Summary

THR (Total Hip Replacement) can be very painful and regional anesthesia is very effective in reducing postoperative pain. Erector Spinae Plane Block (ESPB) and PENG (pericapsular nerve group block) are alternative approaches to the hip sensitive nerve branches that resulted to be very promising for hip surgeries. However, no studies investigated the analgesic superiority of either PENG or ESPB. In our study the investigators compare PENG (with a lateral femoral cutaneous nerve block) and ESPB in terms of pain relief expressed as morphine consumption in the first 24 hours after primary THR.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • primary total hip replacement
  • informed consent

Exclusion Criteria

  • allergies to study drugs
  • spinal anesthesia contraindicated
  • kidney failure
  • epilepsy, psychiatric disease, neurologic deficits
  • revision surgery
  • neuropathies in the lumbar area
  • no informed consent
  • pregnancy
  • alcohol/opioid abuse
  • emergency surgery/intensive care

Outcomes

Primary Outcomes

morphine consumption

Time Frame: 24 hours

milligrams of morphine by patient controlled analgesia intravenously

Secondary Outcomes

  • postoperative pain(48 hours)
  • chronic postoperative pain(3 months)
  • neuropathic pain(48 hours)
  • postoperative complications(48 hours)

Investigators

Sponsor
Papa Giovanni XXIII Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dario Bugada

MD

Papa Giovanni XXIII Hospital

Study Sites (2)

Loading locations...

Similar Trials